Cellectis S.A.
NASDAQ:CLLSBiotechnology
Healthcare
$1.06 -0.65%
-$0.02 today
- Market cap
- $106.78M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
52W Low $1.35High $5.48
Volume 0.02M
Average 0.04M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$40.14M
FY 2025 · Annual
Investing Cash Flow
-$29.58M
FY 2025 · Annual
Financing Cash Flow
-$16.20M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (96.75M) | (98.69M) | (116.84M) | (36.7M) | (67.8M) |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.84M | 20.12M |
| Deferred Income Tax | 0 | 87K | 371K | 0 | 0 |
| Stock-Based Compensation | 11.49M | 6.04M | 5.23M | 0 | 0 |
| Change in Working Capital | (12.3M) | (5.72M) | (3.99M) | 53.57M | (41.72M) |
| Accounts Receivables | (12.44M) | (8.99M) | 2.25M | (6.72M) | (4.44M) |
| Inventory | 215K | 0 | 0 | 0 | 0 |
| Accounts Payables | 177K | 3.25M | (6.31M) | 2.05M | (3.27M) |
| Other Working Capital | (252K) | 23K | 67K | 58.24M | (34.01M) |
| Other Non-Cash Items | (21.17M) | (7.6M) | 71.95M | (14.61M) | 49.26M |
| Operating Cash Flow | (104.56M) | (87.44M) | (24.75M) | 22.1M | (40.14M) |
| Capital Expenditures | (18.56M) | (2.44M) | (1.07M) | (2.58M) | (2.37M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (143K) | 0 | 0 | (162.48M) | (160.27M) |
| Sales of Investments | 15M | 126K | 0 | 63.69M | 134.24M |
| Other Investing Activities | 10.97M | (456K) | (14.44M) | 0 | 0 |
| Investing Cash Flow | 7.28M | (2.76M) | (15.51M) | (102.63M) | (29.58M) |
| Debt Repayment | (10.64M) | (6.6M) | 24.56M | 18.17M | (5.4M) |
| Common Stock Issued | 44.64M | 0 | 67.94M | 82.68M | 44.14K |
| Common Stock Repurchased | 0 | (569K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.53M | 8.32M | (9.64M) | (11.04M) | (10.85M) |
| Financing Cash Flow | 47.53M | 1.15M | 82.87M | 89.8M | (16.2M) |
| Effect of Forex Changes | (5.75M) | (3.36M) | 884K | (2.73M) | 6.24M |
| Net Change in Cash | (55.51M) | (92.42M) | 43.49M | 6.54M | (79.67M) |
| Free Cash Flow | (123.12M) | (89.89M) | (25.82M) | 19.52M | (42.5M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$67.8M
+ D&A$20.1M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$41.7M
+ Other Non-Cash$49.3M
= Operating Cash Flow-$40.1M
- Capex-$2.4M
= Free Cash Flow-$42.5M
Analysis
FY2025 free cash flow is -$42.5M. FCF conversion is 62.7% of net income. Operating cash flow was -$40.1M, with capex of -$2.4M. The largest bridge item is Other Non-Cash at $49.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 13, 2026 | |
| 6-K | 6-K filing | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 9, 2026 | |
| 6-K | 6-K filing | Nov 9, 2026 | |
| 6-K | 6-K filing | Oct 28, 2026 |
Does CLLS generate free cash flow?
Cellectis S.A. (CLLS) generated -$42.50M of free cash flow in fiscal 2025.
How much operating cash flow does CLLS produce?
Operating cash flow was -$40.14M, before capital expenditures of $2.37M.
Continue the stock analysis
Jump to another research area for this company.